Seelos Therapeutics, Inc. (SEEL) financial statements (2021 and earlier)
Company profile
| Business Address |
300 PARK AVENUE NEW YORK, NY 10017 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 16 | 10 | 4 | 6 | 2 | 4 | 11 | ||
| Cash and cash equivalents | 16 | 10 | 4 | 6 | 2 | 4 | 11 | ||
| Restricted cash and investments | 0 | 0 | |||||||
| Receivables | 1 | 1 | 1 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 1 | 0 | 0 | ||||||
| Inventory | 1 | 0 | 0 | ||||||
| Other undisclosed current assets | 2 | 1 | 0 | 0 | 0 | 1 | 1 | ||
| Total current assets: | 17 | 11 | 4 | 7 | 4 | 6 | 13 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | 0 | 1 | 1 | 1 | ||||
| Other noncurrent assets | 0 | 0 | 0 | 0 | 0 | ||||
| Total noncurrent assets: | 0 | 0 | 1 | 2 | 2 | ||||
| TOTAL ASSETS: | 17 | 11 | 4 | 7 | 5 | 8 | 15 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 4 | 3 | 1 | 2 | 5 | 6 | 7 | ||
| Accounts payable | 2 | 1 | 0 | 0 | 1 | 2 | 1 | ||
| Accrued liabilities | 2 | 2 | 1 | 1 | 3 | 3 | 5 | ||
| Employee-related liabilities | 0 | 1 | 1 | 1 | 1 | ||||
| Debt | 2 | 7 | 9 | 0 | |||||
| Deferred compensation liability | 0 | ||||||||
| Derivative instruments and hedges, liabilities | 1 | 1 | |||||||
| Accrued environmental loss contingencies | 0 | ||||||||
| Disposal group, including discontinued operation | 0 | ||||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 0 | 0 | 0 | |||
| Other undisclosed current liabilities | 0 | 7 | (0) | ||||||
| Total current liabilities: | 7 | 11 | 1 | 2 | 11 | 16 | 7 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 7 | 5 | |||||||
| Long-term debt, excluding current maturities | 7 | 5 | |||||||
| Capital lease obligations | ✕ | ✕ | 0 | ||||||
| Liabilities, other than long-term debt | 0 | 1 | 1 | 2 | 2 | ||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 1 | |||||
| Deferred compensation liability, classified | 0 | ||||||||
| Other liabilities | 0 | 0 | 0 | 0 | 0 | ||||
| Derivative instruments and hedges, liabilities | 1 | 1 | 2 | ||||||
| Other undisclosed noncurrent liabilities | 0 | 0 | (0) | ||||||
| Total noncurrent liabilities: | 7 | 0 | 0 | 1 | 1 | 2 | 6 | ||
| Total liabilities: | 15 | 11 | 1 | 2 | 12 | 18 | 13 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 3 | (0) | 3 | 4 | (8) | (10) | 2 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 78 | 56 | 328 | 320 | 309 | 299 | 292 | ||
| Accumulated deficit | (75) | (56) | (325) | (316) | (316) | (309) | (290) | ||
| Total stockholders' equity: | 3 | (0) | 3 | 4 | (8) | (10) | 2 | ||
| TOTAL LIABILITIES AND EQUITY: | 17 | 11 | 4 | 7 | 5 | 8 | 15 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 0 | 0 | 1 | 6 | 5 | 9 | ||
| Revenue, net | ✕ | ✕ | ✕ | 1 | 6 | 5 | 9 | |
| Net investment income | 0 | 0 | ||||||
| Cost of revenue (Cost of Goods and Services Sold) | (4) | (1) | (1) | |||||
| Gross profit: | 0 | 0 | 1 | 2 | 4 | 8 | ||
| Operating expenses | (19) | (30) | (9) | (11) | (15) | (25) | (31) | |
| Other undisclosed operating loss | (0) | (1) | ||||||
| Operating loss: | (19) | (30) | (9) | (11) | (13) | (21) | (23) | |
| Nonoperating income (expense) | (0) | (22) | (0) | (1) | 6 | 2 | 0 | |
| Investment income, nonoperating | 1 | |||||||
| Gain on contract termination | 1 | |||||||
| Other nonoperating income (expense) | 0 | 0 | (0) | (0) | 1 | |||
| Interest and debt expense | (0) | (0) | (0) | (1) | (1) | (0) | ||
| Loss from continuing operations before income taxes: | (19) | (51) | (9) | (12) | (8) | (20) | (23) | |
| Other undisclosed income from continuing operations | 0 | |||||||
| Loss from continuing operations: | (19) | (51) | (9) | (12) | (8) | (20) | (22) | |
| Income from discontinued operations | 1 | |||||||
| Net loss: | (19) | (51) | (9) | (12) | (8) | (20) | (22) | |
| Other undisclosed net income (loss) attributable to parent | 0 | 0 | (0) | 12 | 1 | 1 | ||
| Net income (loss) available to common stockholders, diluted: | (19) | (51) | (9) | 0 | (7) | (19) | (22) | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (19) | (51) | (9) | (12) | (8) | (20) | (22) | |
| Comprehensive loss, net of tax, attributable to parent: | (19) | (51) | (9) | (12) | (8) | (20) | (22) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.